Complications of allogeneic hematopoietic stem cell transplantation (HSCT) remain barriers
to its wider application for a variety of diseases. Graft-versus-host disease (GVHD) is the …

Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of
allogeneic bone marrow transplantation (BMT). The immunobiology of acute GVHD is …

Summary Interleukin-2 (IL-2) regulates lymphocyte function by signaling through
heterodimerization of the IL-2Rβ and γ c receptor subunits. IL-2 is of considerable …

Bone marrow transplantation (BMT) is the treatment of choice for many leukemias, solid
tumors, and metabolic diseases. The field of bone marrow research is highly dependent on …

Daclizumab, a humanized monoclonal IgG1 directed against the chain of the interleukin-2
receptor (IL-2R), is a competitive inhibitor of IL-2 on activated lymphocytes. To test the …

The major complication after allogeneic bone marrow transplantation (BMT) is the
development of graft-versus-host-disease (GVHD). This disease is initiated during the …

Graft‐versus‐host disease (GVHD) has been the primary limitation to the wider application
of allogeneic bone marrow transplantation (BMT). The pathophysiology of acute GVHD is …

Graft-versus-host disease (GvHD) was first described in mice by Barnes and Loutit in
1955.13 The term graft-versus-host was introduced later to describe an immunological entity …

Graft-versus-host disease (GVHD) is the major complication after allogeneic bone marrow
transplantation (BMT) and is initiated by alloreactive donor T cells recognizing foreign …

Highly purified populations of L3T4+ and Lyt-2+ T cell subsets were compared for their
capacity to cause lethal GVHD in six different H-2-compatible, multiple minor …